Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

T-Up/Astec Biologics criminal charges

This article was originally published in The Tan Sheet

Executive Summary

Firms' President Allen Hoffman sentenced Nov. 30 to 46 months in federal prison, ordered to pay $222,506 restitution after pleading guilty to two counts of introducing unapproved new drug (aloe vera compounds) into interstate commerce with intent to defraud. A Baltimore federal jury had deadlocked on all but one charge against Hoffman and T-Up in a June 2000 trial (1"The Tan Sheet" July 3, 2000, In Brief). Hoffman marketed products as treatments for cancer, other diseases...

You may also be interested in...



T-Up, Inc.

Baltimore firm and its principals are appealing a $3.7 mil. fine by the Maryland Attorney General for making claims their aloe vera and mineral health products cure diseases such as cancer and AIDS. T-Up products were marketed for oral consumption or IV administration without FDA approval and lacked adequate safety and efficacy data, the AG asserted. T-Up, President Allen Hoffman and two others were indicted in July 1999 on federal charges of conspiracy, mail and wire fraud and introducing an unapproved new drug into commerce. A Baltimore federal jury on June 15 deadlocked on all but one charge against the firm and Hoffman, finding them not guilty on one mail fraud count. The jury found an Oklahoma supplier of the products not guilty on all counts

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel